cCAM Biotherapeutics develops novel immunotherapies for cancer. cCAM’s lead agent, CM-24, is an immunomodulatory antibody that blocks a novel immune checkpoint, thereby harnessing  the patient’s immune system to attack tumors. In July 2015, the company was acquired by Merck.

biopharmaceuticals
Acquired by Merck
Visit Website
Additional Portfolio Companies
Adicet Bio
AgomAb Therapeutics
ArQule
Cathworks
Camel-IDS
Dynacure
cCAM Biotherapeutics
CheckCap
Eloxx Pharmaceuticals
Enlivex Therapeutics
Eyevensys
EyeYon
ForSight Vision6 (“V6”)
Horama
IMEL Biotherapeutics
Kamari Pharma
Keros Therapeutics
Kite Pharma
Levation Pharma
LogicBio Therapeutics
Lutris Pharma
Mereo BioPharma
Metabomed
NovellusDX
Ocon Medical
Prevail Therapeutics
PACT Pharma
Pi Therapeutics
Protalix
Raziel Therapeutics
ReWalk
SilverBack Therapeutics
Stargazer Pharmaceuticals
VBI Vaccines
Step Pharma
StimatixGI
Sweetch
TargEDys
Vascular Graft Solutions
UroGen
V-Wave
July 12, 2015